Sutro Biopharma Inc
Company Profile
Business description
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Contact
111 Oyster Point Boulevard
South San FranciscoCA94080
USAT: +1 650 881-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
244
Stocks News & Analysis
stocks
Undervalued ASX share with plan to mitigate tariff risk
stocks
Earnings up but shares overvalued for ASX gold miner
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,295.80 | 26.20 | -0.28% |
| CAC 40 | 8,216.58 | 22.60 | -0.27% |
| DAX 40 | 24,278.63 | 30.15 | -0.12% |
| Dow JONES (US) | 47,706.37 | 161.78 | 0.34% |
| FTSE 100 | 9,696.74 | 42.92 | 0.44% |
| HKSE | 26,346.14 | 87.56 | -0.33% |
| NASDAQ | 23,827.49 | 190.04 | 0.80% |
| Nikkei 225 | 50,219.18 | 293.14 | -0.58% |
| NZX 50 Index | 13,458.66 | 56.00 | 0.42% |
| S&P 500 | 6,890.89 | 15.73 | 0.23% |
| S&P/ASX 200 | 9,012.50 | 16.30 | -0.18% |
| SSE Composite Index | 3,988.22 | 8.72 | -0.22% |